Items where authors include "Heath, P.T."

Export as [feed] Atom [feed] RSS
Jump to: Article
Number of items: 5.

Article

Lee, I.T., Cosgrove, C.A., Moore, P. et al. (63 more authors) (2023) Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial. The Lancet Infectious Diseases. ISSN 1473-3099

Shaw, R.H., Greenland, M., Stuart, A.S.V. et al. (37 more authors) (2023) Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection, 86 (6). pp. 574-583. ISSN 0163-4453

Miller, P.D.E., Patel, S.R., Skinner, R. orcid.org/0000-0002-1162-675X et al. (9 more authors) (2023) Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children's cancer and Leukaemia Group (CCLG), and British Infection Association (BIA). Journal of Infection, 86 (1). pp. 1-8. ISSN 0163-4453

Shaw, R.H., Liu, X., Stuart, A.S.V. et al. (81 more authors) (2022) Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. The Lancet Respiratory Medicine, 10 (11). pp. 1049-1060. ISSN 2213-2600

Stuart, A.S.V., Shaw, R.H., Liu, X. et al. (40 more authors) (2022) Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet, 399 (10319). pp. 36-49. ISSN 0140-6736

This list was generated on Sat Apr 20 20:10:27 2024 BST.